View More Recent Stories

Jun 17, 2016 07:00AM Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 22, 2016
Jun 16, 2016 07:00AM Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis
Jun 15, 2016 07:05AM Corbus Pharmaceuticals Completes $15 Million Registered Direct Offering
Jun 10, 2016 09:27AM Corbus Pharma (CRBP) Enters $15M Securities Purchase Agreement
Jun 10, 2016 09:25AM Corbus Pharmaceuticals Announces $15 Million Registered Direct Offering
May 16, 2016 08:13AM Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update
Apr 12, 2016 07:31AM Corbus Pharma (CRBP) Receives FDA Approval for Resunab Phase 2 Extension Study
Apr 12, 2016 07:30AM Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis
Mar 31, 2016 07:35AM Corbus Pharma (CRBP) Files Amendment for Resunab Phase 2 IND as SLE Treatment
Mar 31, 2016 07:30AM Corbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND
Mar 29, 2016 07:30AM Corbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016 Business Update
Mar 7, 2016 07:36AM Corbus Pharma (CRBP) to Commence Resunab Phase 2 in SLE
Mar 7, 2016 07:35AM Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus
Feb 1, 2016 07:05AM Corbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016
Jan 5, 2016 07:05AM Corbus Pharmaceuticals to Present at Biotech Showcase(TM) on January 12, 2016
Nov 23, 2015 07:05AM Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015
Nov 11, 2015 07:05AM Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results
Oct 20, 2015 08:05AM Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
Oct 15, 2015 07:30AM Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis
Oct 13, 2015 07:00AM Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
Oct 7, 2015 07:05AM Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis
Sep 22, 2015 07:00AM Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis
Sep 21, 2015 07:00AM Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis
Aug 31, 2015 08:05AM Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Systemic Sclerosis
Aug 27, 2015 08:05AM Corbus Pharmaceuticals Successfully Completes Warrant Call -- Raises $11.3 mm in Total From 100% Exercise of Callable Warrants
Aug 19, 2015 07:35AM Corbus Pharmaceuticals' Investigational Drug Resunab(TM) Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis
Aug 13, 2015 07:05AM Corbus Pharmaceuticals Reports 2015 Second Quarter Financial Results and Provides Business Update
Aug 6, 2015 07:35AM Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
Apr 16, 2015 10:00AM Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
Apr 16, 2015 10:00AM Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories